前列腺素E1与福辛普利联合治疗糖尿病肾病疗效分析

• 作 者: 林宏初 吴恒莲 刘国辉 阮雪玲 区冰玲 郑东文 彭伟成
• 机 构: 广东省东莞市人民医院肾内科,广东省东莞市人民医院肾内科,广东省东莞市人民医院肾内科,广东省东莞市人民医院肾内科,广东省东莞市人民医院肾内科,广东省东莞市人民医院肾内科,广东省东莞市人民医院肾内科 52
• 出 处: 中国实用内科杂志
• 发表日期: 2004年09期
• 关键词: 前列腺素E1 脂微球载体制剂 福辛普利 糖尿病肾病 尿白蛋白排泄率 肾功能

目的　观察前列腺E1(LipoPGE1)与福辛普利联合治疗早期糖尿病肾病 (DN)和肾功能正常的临床糖尿病肾病 (DN)的疗效。方法　将 86例 2型DN患者随机分为对照组 (福辛普利 )和治疗组 (福辛普利 +LipoPGE1)。比较两组治疗前和治疗后 8周UAER、Scr和BUN等指标的变化。结果　 (1)治疗后治疗组和对照组UAER均显著下降 (P <0 0 5 ,P <0 0 1) ,治疗组比对照组下降更为明显 (P <0 0 5 )。 (2 )治疗后治疗组Scr显著下降 (P <0 0 5 ) ,而对照组则无明显改变。 (3)治疗后两组BUN、FBG、MPA、TC和TG均无明显变化。结论　LipoPGE1和福辛普利联合治疗能有效减少早期DN和肾功能正常的临床DN患者的蛋白尿 ,改善肾功能。

Objective To observe the clinical efficacy of LipoPGE1 and fosinopril in the treatment of early diabetic nephropathy (DN) and normal diabetic nephropathy (DN). Methods Totally 86 patients with type 2 DN were randomly divided into control group (fosinopril) and treatment group (fosinopril + LipoPGE1). The changes of UAER, Scr and BUN before and 8 weeks after treatment were compared between the two groups. Results (1) After treatment, the UAER of the treatment group and the control group decreased significantly (P <0.05, P <0.01), and the treatment group decreased more significantly than the control group (P <0.05). (2) After treatment, Scr in treatment group decreased significantly (P <0.05), but no significant change in control group. (3) There was no significant change in BUN, FBG, MPA, TC and TG after treatment in both groups. Conclusions LipoPGE1 combined with fosinopril can effectively reduce proteinuria and improve renal function in patients with early DN and clinical DN with normal renal function.